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In November 2007, ISPOR convened the “Building a Pragmatic
Road: Moving the QALY Forward” Consensus Development
Workshop where thought leaders presented and discussed the
following: 1) deﬁning and reﬁning the quality-adjusted life-year
(QALY) by analyzing the underlying assumptions; 2) developing
alternative paradigms and measures; 3) retaining the QALY and
enhancing it with additional methods; and 4) incorporating a
variety of decision-makers’ needs. The goal of this workshop on
the QALY was to reach consensus among the thought leaders on
these broad categories, with recommendations for speciﬁc, appli-
cable actions. Workshop participants are listed below.
Before this workshop, participants were divided into ﬁve
groups and each group met via teleconference to develop their
arguments on one of the following topics: 1) deﬁning the QALY;
2) considering alternate deﬁnitions of the QALY and deﬁning
the issues; 3) incorporating an experience-based approach to the
QALY; 4) deﬁning the importance of bridging past QALY infor-
mation to future QALY information; and 5) deﬁning the value of
the QALY from a health-care decision-makers’ perspective.
Using a modiﬁed “forming–storming–norming–performing”
model [1] for consensus development during the 2-day work-
shop, each group presented arguments about the QALY, received
feedback on their arguments and modiﬁed, if needed. Then a
group of representatives from each group was convened to
develop consensus statements on “moving the QALY forward”
based on the arguments presented. These consensus statements
were then debated, and agreed upon by workshop participants,
and then formulated into the ﬁnal article in this Special Issue.
This Value in Health Special Issue describes the arguments
presented during the consensus development workshop on the
QALY. Articles 2–6, “QALYs: The Basics,” “QALYs: Some Chal-
lenges,” “A Different Approach to Health State Valuation,”
“Retaining, and Enhancing, the QALY,” and “The Use of QALYs
in Clinical and Patient Decision-Making: Issues and Prospects,”
present the arguments. Article 7, “Towards a Consensus on the
QALY,” deﬁnes eight consensus statements developed by the
“consensus developing group” and presents a way forward.
The last two articles in this Special Issue, “Editorial: On The
Beneﬁts of Modeling Using QALYs for Societal Resource Allo-
cation: The Model Is the Message” and “Editorial: Moving The
QALY Forward or Just Stuck in Trafﬁc?” are provided by two
guest editors, selected by the Value in Health Editor-in-Chief to
critique this Special Issue. The appointment of guest editors is an
important component of Value in Health’s policy on Special
Issues and is intended to ensure that a broad range of views is
expressed. The guest editors did not participate in the QALY
Consensus Development Workshop, so their reactions are based
on the written articles alone.
Garrison is broadly welcoming of this initiative and considers
that the articles in this Special Issue are a fair and useful repre-
sentation of the current debate about health state utilities and
preferences. Nevertheless, he also points out that several impor-
tant issues were not discussed, or not resolved satisfactorily. He
also points out that the relevance of QALYs for resource alloca-
tion may depend crucially on the values underlying the organi-
zation of the health-care system in a given country. For example,
QALYs may have a different relevance in a country like the
United Kingdom, with a government-funded national health
service, than they may have in a country like the United States.
On the other hand, Reed Johnson is much more frustrated
with the lack of progress with research within the QALY para-
digm and feels that more progress would be made if we looked
for alternatives. These could be alternative methods for elucidat-
ing preferences, such as contingent valuation and discrete choice
experiments, or different decision-making approaches, such as
that currently being proposed by the Institute for Quality and
Efﬁciency in Health Care in Germany. We support further
research into, and experimentation with, alternatives to the
QALY. As these approaches become more often used in practice,
their difﬁculties will become better known and, hopefully,
resolved. Nevertheless, the focus on this workshop was on expe-
rience with the QALY. Perhaps, similar workshops, discussing
experiences with using alternative measures, will be possible in
the future.
We hope that this Value in Health Special Issue on “Moving
the QALY Forward: Building a Pragmatic Road” is both infor-
mative and serves as a platform for future debate and consensus
development on the QALY.
Background
The QALY is a widely used measure of both quantity and
quality of life. Its beneﬁt for health-care evaluation is that it is
applicable to “all individuals and all diseases” and can there-
fore be used to compare interventions across diseases and pro-
grams [2]. It is thus particularly important to outcomes
researchers as they attempt to evaluate the efﬁcacy and cost of
various health-care interventions and to health-care decision-
makers as they weigh implementation or purchase of health-
care technologies, including diagnostics, devices, and
medications. The QALY is particularly useful because it enables
comparisons across diseases, populations, and programs. Some
health-care systems, such as the National Institute for Health
and Clinical Excellence (NICE) of the British National Health
Service (NHS) use QALYs to determine health-care priorities
[3]. QALYs are also used in population health, to measure and
compare the health of a community.
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There are several elements to the estimation of QALYs, many
of which raise methodological issues. The main element is the
assignment of preference values, sometimes known as “utilities”
to different health states. To accomplish this, health states need to
be classiﬁed and described to a respondent, who then values them
relative to one another, or an anchor point such as death. Several
classiﬁcation systems exist and these are particularly important
in the case of the generic health utility measures, such as the
EQ-5D or the Health Utilities Index (HUI).
There are also alternative approaches for eliciting the health
state preference values, such as the standard gamble, the time
trade-off, and the person trade-off. Each approach has its own
underlying rationale and, in some cases, set of axioms. Another
key issue is that of “whose values” should be used as the source
of values, the candidates including patients, decision-makers, and
the general public. The weights or value “tariffs” of all the
generic measures are based on surveys of the general public,
although the EQ-5D also includes an assessment of self-rated
health, which would be from patients when the measure is used
in the context of a clinical study.
A second element in the estimation of QALYs is the construc-
tion of the proﬁle of health state values over time. In estimating
the QALYs gained from a health-care intervention, the analyst
calculates the area under the curve, that is, the difference between
the proﬁles obtained for the treatment of interest and its com-
parator. The simplest, and most frequently used, approach for
estimating the proﬁle is to multiply the time spent in each health
state over time with its corresponding health state value. Never-
theless, some researchers argue that it is better to estimate the
proﬁle holistically, because the value of a given health state is not
independent of the time spent in it, or the order in which it is
experienced.
A third major element in estimating the total QALYs gained
from a given health-care intervention is the aggregation of
QALYs across all the recipients. The standard approach is to
treat all QALYs gained as being equal, no matter to whom they
accrue. Nevertheless, this approach is questioned by some who
argue that QALYs may have a different weight depending on, for
example, the individual’s initial health state, or the state to which
their health is raised.
As the deﬁnition, methods, alternatives, and evolution of
the QALY are debated, one needs to understand how this tool
is being used in health technology assessment and reimburse-
ment decisions. The ultimate use of the tool should be consid-
ered in each of the previously described development steps of
the QALY to assure continuous improvement in the quality of
decisions being made using this tool. The perspective of the end
user plays a critical role. In the United Kingdom, a country
with a single-payer health system and a clear societal perspec-
tive in technology assessment, the QALY seems particularly
well utilized in decision-making. This has been demonstrated
by the health economist experts who participate on the NICE
Review Board for the NHS. The cost and beneﬁt of a technol-
ogy is summarized in a cost per QALY measure, and standards
have been set to create a threshold (generally £30,000 per
QALY) of what is acceptable to society. On the other hand,
because of a decentralized, fragmented health-care system in
the United States, the payers often have different perspectives in
making health-care decisions, and these perspectives may or
may not include the concept of quality of life. The QALY may
be highly relevant to a single payer such as Medicare; however,
the drug beneﬁt for the elderly is delivered through an unco-
ordinated private payer system [4]. There is also a difference in
how the QALY is used, for example, as a measure of efﬁcacy
for registration or as a utility measure in a cost-effectiveness
ratio for reimbursement. Across the various perspectives and
potential uses of the QALY, consistency is a key objective. If
alternative deﬁnitions, methods, and approaches are used to
accommodate differences in perspective, the complexity will
inhibit the practical application of the QALY in making better
decisions on the allocation of scarce resources in health care.
Thus, despite its beneﬁts and wide use, the methodology and
results of attempts to estimate QALYs have been the subject of
debate in the health-care ﬁeld for some time. Outcomes research-
ers have discussed whether the preference weights required by the
measure should come from patients or the community, as pre-
ferences between these two groups can differ [2,5]. In addition,
different measures used to calculate QALYs, such as the HUI and
the EQ-5D, may yield results that are not directly comparable
[2,6], and thus not optimal for truly informed decision-making.
Finally, decision-makers themselves question whether the QALY
can be meaningful in all instances: some feel that the beneﬁts of
certain medications that improve the quality of life, such as those
for arthritis, cannot be adequately measured by life-years sur-
vived. Moreover, some fear that models using QALYs might
result in interventions that enhance the quality of life, such as
erectile dysfunction medications, appearing a better use of
resources than interventions that might extend or save life, such
as dialysis or bypass surgery [7].
Perhaps more importantly, the fundamental assumptions
behind the QALY have begun to be questioned. Daniel Kahne-
man, the Eugene Higgins Professor of Psychology and Professor
of Public Affairs at the Woodrow Wilson School, Princeton Uni-
versity, and a 2002 winner of the Nobel Prize in Economic
Sciences, has observed that “QALYs obtained from patients and
the QALYs obtained from the public are going to be radically
different. This is because the public and the patients have differ-
ent reference points” [8]. In a 2005 plenary presentation at the
ISPOR 10th Annual International Meeting [9], Kahneman noted
that the experience of patients is often quite different from
outside observers expect it to be. Studies show that paraplegics,
for example, suffer a tremendous negative impact when the con-
dition ﬁrst occurs, but that the impact moderates over time,
which is not expected by outside observers, asked to estimate the
effect of such a condition. Paraplegics integrate their condition
with other life events and focus less on their condition as time
goes by. Such discrepancies highlight the need for a measure that
takes patient’s experience into account. Professor Kahneman
outlined a paradigm shift between decision utility, which under-
lies the QALY and is based on inference of choice, and behavioral
economics (experienced utility), which is a relatively new ﬁeld
interested in developing optimal methods of measuring patients’
experience [10].
Among outcomes researchers, the interest in deﬁning and
using the most meaningful paradigm has stimulated an interest in
reviewing the underlying tenets of the ﬁeld. George Torrance,
emeritus professor at McMaster University, has argued that,
because the measures used were generated from diverse ﬁelds
such as economics and decision sciences and then applied to
health care, the results may not be fully comparable unless the
underlying axioms are speciﬁed adequately [11].
In a 2006 Issue Panel debate at the 11th Annual ISPOR
International Meeting, Dennis Fryback argued that outcomes
researchers, health-care professionals, and decision-makers con-
cerned with questioning the QALY, however, are counterbal-
anced by another group who argues that the QALY serves a
function in health care analogous to the Dow Jones Industrial
Average in ﬁnance: a useful, if not comprehensive, benchmark
understood by all participants and possessing a long history [5].
In addition, some health-care researchers contend that the lack of
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a simple better measure as an alternative makes the QALY an
indispensable tool. Finally, there is a cluster of questions center-
ing not so much on the QALY per se but around issues of its
augmentation or replacement. Many outcomes researchers focus
on a simple question: if not the QALY, then what? What
would—or could—replace the QALY?
During the 2006 Issues Panel debate, Professor Kahneman
suggested that researchers think of what an ideal measure might
be, and suggested research into potential tools utilizing the dis-
cipline of behavioral economics. Professor Fryback suggested
that research and decision-making, in addition to pragmatically
using the QALY, could beneﬁt the development of a broader set
of data and methods. As noted above, he itemized several addi-
tional methods as a starting point: 1) better use of public delib-
erative processes for valuing health descriptive systems; 2) the
collection of data about, exploration of, and integration of lon-
gitudinal observations of the health experience of people into the
community’s deliberative process; and 3) more routine collection
and use of existing health-related indexes.
ISPOR Consensus DevelopmentWorkshop on
Moving the QALY Forward
Given the QALY’s overall importance to the measurement of
health care, its modiﬁcation, enhancement, or replacement
would have signiﬁcant potential to change health-care method-
ology and stimulate research going forward. Therefore, ISPOR
convened a 2-day invitational consensus development workshop
on “Moving the QALY Forward,” November 7–8, 2007, Phila-
delphia, PA, USA with thought leaders in the ﬁeld with the goal
to advance the knowledge in this ﬁeld, to clarify or transform
concepts and methods that drive the ﬁeld, and to deﬁne a
research agenda.
The tenets and issues presented and debated at this workshop
were as follows.
QALYs: The Basics
The deﬁnition of a QALY as a weighted life-year and the tax-
onomy of methods for deriving those weights were presented and
debated.
QALYs: Some Challenges
The development of alternate or preferred deﬁnitions of the
QALY, deﬁning the metric of the QALY, listing the assumptions,
and deﬁning the validity of these assumptions were also pre-
sented and debated.
A Different Approach to Health State Valuation
Because experience-based utility may complicate the QALY, a
proposal to establish citizen’s juries for health state valuation
was presented. In addition, the importance of including efﬁ-
ciency, distributive, and procedural justice in the health-care
decision-making process was presented.
Retaining, and Enhancing, the QALY
The need to 1) to take stock of current data sets; 2) to outline
ways of integrating new work with existing data; and 3) to
determine the strengths and weaknesses of existing methods were
presented and debated.
The Use of QALYs in Clinical and Patient
Decision-Making: Issues and Prospects
The use of measures, such as the QALY, relate to profound social
decisions. An improvement in health outcomes might not be the
only reason to use the QALY: other reasons are overall improve-
ment of societal welfare or as an indicator of society’s care and
compassion. The need to 1) identify how to optimize public
deliberative processes for valuing health; 2) discuss barriers in
decision-makers’ adoption and use of the QALY, with a view
toward strategizing improvement of the measure or improvement
of decision-makers’ understanding; and 3) formulate what the
user wants and develop a guide to decision-maker identiﬁcation
of issues for outcomes researchers were presented and discussed.
ISPOR Consensus DevelopmentWorkshop on
Moving the QALY Forward Attendees
The following thought leaders participated in the development of
the ﬁve group presentations: Diana Brixner, BSPharm, PhD, Uni-
versity of Utah, Salt Lake City, UT, USA; Karl Claxton, MSc,
PhD (participated in teleconferences but unable to attend con-
sensus workshop), University of York, York, UK; Norman
Daniels, PhD, Harvard University School of Public Health,
Boston, MA, USA; Paul Dolan, DPhil, University of Shefﬁeld,
Shefﬁeld, UK; Michael Drummond, DPhil, University of York,
UK; Dennis G. Fryback, PhD, University of Wisconsin-Madison,
Madison, WI, USA; Marthe Gold, MD, MPH, City University of
New York Medical School, New York, NY, USA; Daniel Kahne-
man, PhD, Princeton University, Princeton, NJ, USA; Mark Scott
Kamlet, PhD, Carnegie Mellon University, Pittsburg, PA, USA;
Paul Kind, University of York, York, UK; Jennifer Elston Lafata,
PhD, Henry Ford Health System, Detroit, MI, USA; Joseph Lip-
scomb, PhD, Rollins School of Public Health, Atlanta, GA; Karl
Matuszewski, MS, PharmD, University HealthSystem Consor-
tium, Oak Brook, IL, USA; Alistair McGuire, PhD, London
School of Economics, London, UK; Erik Nord, PhD, Norwegian
Institute of Public Health, Oslo, Norway; Dennis Raisch
BSPharm, PhD, University of New Mexico Health Sciences
Center, Albuquerque, NM, USA; Dennis Revicki, PhD, United
BioSource Corp., Bethesda, MD, USA; George Torrance, PhD,
McMaster University, Toronto, Canada; Milton C. Weinstein,
PhD, Harvard University School of Public Health, Boston, MA,
USA.
The following attendees also participated in the discussions
during the 2-day workshop: Martin L Brown, PhD, National
Cancer Institute, Bethesda, MD, USA; Steven Clauser, PhD,
National Cancer Institute, Bethesda, MD, USA; William
Lawrence, MD, DrPH, Agency for Healthcare Research and
Quality, Rockville, MD, USA; Andreas Maetzel, PhD, MD, MSc,
Amgen (Europe) GmbH, Zug, Switzerland; Bryce Reeve, PhD,
National Cancer Institute, Bethesda, MD, USA; James A. Shut-
tinga, PhD, Ofﬁce of the Director, National Institutes of Health,
Bethesda, MD, USA.
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